Holen Sie sich die Stockscreener-App
2.90
8.21%
0.22
Schlusskurs vom Vortag:
$2.68
Offen:
$2.7
24-Stunden-Volumen:
241.36K
Relative Volume:
1.50
Marktkapitalisierung:
$115.43M
Einnahmen:
$2.70M
Nettoeinkommen (Verlust:
$5.53M
KGV:
26.36
EPS:
0.11
Netto-Cashflow:
$-10.55M
1W Leistung:
+6.62%
1M Leistung:
+27.19%
6M Leistung:
+30.04%
1J Leistung:
+15.54%
1-Tages-Spanne:
$2.69
$2.92
1-Wochen-Bereich:
$2.66
$2.92
52-Wochen-Spanne:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Vergleichen Sie ORMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.90 | 106.67M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
How strong dollar benefits Oramed Pharmaceuticals Inc. (OJU1) stockJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - Newser
Why Oramed Pharmaceuticals Inc. stock appeals to analystsJobs Report & Free AI Powered Buy and Sell Recommendations - Newser
Will Oramed Pharmaceuticals Inc. stock gain from strong economyJuly 2025 Selloffs & Free Fast Gain Swing Trade Alerts - Newser
Will Oramed Pharmaceuticals Inc. (OJU1) stock maintain strong growthRate Hike & Community Verified Trade Signals - Newser
How Oramed Pharmaceuticals Inc. (OJU1) stock correlates with oil markets2025 Short Interest & Stock Market Timing Techniques - Newser
How Oramed Pharmaceuticals Inc. (OJU1) stock valuation compares with sectorJuly 2025 Final Week & Weekly Setup with High ROI Potential - Newser
Is Oramed Pharmaceuticals Inc. (OJU1) stock a buy on weakness2025 Growth vs Value & Technical Pattern Recognition Alerts - Newser
Is Oramed Pharmaceuticals Inc a good long term investmentSector Performance Review & High Yield Trading Growth - earlytimes.in
Is Oramed Pharmaceuticals Inc. (OJU1) stock suitable for passive index funds2025 Key Lessons & Detailed Earnings Play Strategies - BỘ NỘI VỤ
Why Oramed Pharmaceuticals Inc. stock could outperform in 2025CPI Data & Verified Entry Point Detection - BỘ NỘI VỤ
MSN Money - MSN
ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted - Yahoo Finance
Oramed Pharm Repurchases Shares, Ends Joint Venture - MSN
There Are Some Holes In Oramed Pharmaceuticals' (NASDAQ:ORMP) Solid Earnings Release - Yahoo Finance
Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential - simplywall.st
Why Oramed Pharmaceuticals Inc. (OJU1) stock attracts HNW investorsTrade Analysis Report & Expert Approved Momentum Ideas - newser.com
What market sentiment indicators show for Oramed Pharmaceuticals Inc. (OJU1) stockMarket Rally & High Accuracy Trade Signal Alerts - newser.com
Is Oramed Pharmaceuticals Inc. stock overvalued by current metricsBull Run & Consistent Return Strategy Ideas - newser.com
Head-To-Head Comparison: Oramed Pharmaceuticals (NASDAQ:ORMP) and Zimmer Biomet (NYSE:ZBH) - Defense World
How Oramed Pharmaceuticals Inc. (OJU1) stock performs during market turbulence2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Is Oramed Pharmaceuticals Inc. (OJU1) stock vulnerable to rate hikes2025 Top Decliners & AI Driven Price Predictions - newser.com
Is Oramed Pharmaceuticals Inc. (OJU1) stock a fit for income portfoliosQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Is Oramed Pharmaceuticals Inc. stock a top pick in earnings seasonQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com
What recovery options are there for Oramed Pharmaceuticals Inc.Market Performance Summary & AI Powered Market Entry Ideas - newser.com
Can technical indicators confirm Oramed Pharmaceuticals Inc.’s reversal2025 Short Interest & Free Growth Oriented Trading Recommendations - newser.com
Tools to assess Oramed Pharmaceuticals Inc.’s risk profile2025 Historical Comparison & Accurate Intraday Trade Tips - newser.com
Forecasting Oramed Pharmaceuticals Inc. price range with options dataCPI Data & High Return Stock Watch Alerts - newser.com
What sentiment indicators say about Oramed Pharmaceuticals Inc. stock2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - newser.com
Published on: 2025-11-19 00:19:35 - newser.com
Published on: 2025-11-22 06:20:56 - earlytimes.in
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):